期刊文献+

培哚普利和苯磺酸氨氯地平联合应用对高血压蛋白尿的作用 被引量:1

Effect of amlodipine combined with perindopril in patients with hypertension and microalbuminuria
原文传递
导出
摘要 目的观察培哚普利和苯磺酸氨氯地平联合应用治疗高血压蛋白尿的临床疗效。方法将136例高血压合并肾脏损害蛋白尿的患者随机分为A、B两组,A组给予培哚普利4mg/d和苯磺酸氨氯地平5mg/d,B组给予苯磺酸氨氯地平5mg/d和氢氯噻嗪12.5mg/d,均治疗26周。两组治疗前及治疗后测血压、尿白蛋白、尿素氮(BUN)、血肌酐(Scr),并计算肌酐清除率(Ccr)和不良反应。结果两组治疗后6.5个月,血压较前明显下降(P<0.01),两组下降值比较差异无统计学意义(P>0.05)。两组治疗后尿蛋白均下降(P<0.05),A组降低尿蛋白作用比B组更显著(P<0.01)。A组降低Scr、BUN更显著(P<0.05)。结论培哚普利和氨氯地平联合应用能明显较平稳降低高血压,显著减少尿蛋白,有效保护肾功能。 Objective To examine the effects of amlodipine (Amlo) combined with perindopril (peri) used in patients with hypertension and microalbuminuria. Methods One hundi, ed and thirty - six cases in patients with hypertension and microalbuminutia were divided randomly into two groups : group A : amlodipine 5 mg/d + perindopril 4 rag/d, n = 68 ; group B : amlodipine 5 mg/d + 12.5 rag/d, n = 68. Treatment lasted for 26 weeks, parameter of blood pressurel (BP) ,24 h urinary albumin urine protein, blood urea nitrogen, serum creatinine, were measured before and after treatment. Results After treatment 6.5 months, both of two groups reduced blood pressure and proteinuria efficiently. In contrast, the reduction Scr and BUN were reduced more significantly in group A than in group B ( P 〈 0.01 ). Conclusion The therapy of amlodipine combination contrast,the reduction in proteinuria can reduce in proteinuria is greater with perindopril in treating bypertentsive nephropathy with proteinuria can reduce blood pressure markly, produce a better ati - proteinuria effect, and have a better protection of renal function.
出处 《临床医学》 CAS 2009年第7期1-3,共3页 Clinical Medicine
关键词 培哚普利 苯磺酸氨氯地平 高血压 肾脏保护 尿白蛋白 Perindopril Amlodipine Hypertension Renal protection Urinaryalbumin
  • 相关文献

参考文献10

二级参考文献38

  • 1邓先金,曾学丰,缪世海,卿光兰.苯那普利与伊贝沙坦联合用药对高血压患者尿蛋白,血肌酐清除率,血肌酐的影响[J].高血压杂志,2004,12(5):400-403. 被引量:12
  • 2陈楠,陈佳韵.重视微量白蛋白尿的筛查与诊治[J].实用医院临床杂志,2005,2(1):17-19. 被引量:26
  • 3张维忠.降压联合治疗的理论和实践问题[J].中华心血管病杂志,2006,34(5):385-386. 被引量:68
  • 4刘国仗,于汇民.高血压治疗策略的演化[J].中华心血管病杂志,2006,34(7):668-670. 被引量:46
  • 5Remuzzi G, Bertani T. The pathophysiology of progressive nephropathies. N Engl J Med, 1998,339:1448-1456.
  • 6William JD, Coles GA. Proteinuria-a direct cause of renal morbidity? Kidney Int. 1994,45:443-450.
  • 7Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993,329:1456-1462.
  • 8Morelli E, Loon N, Meyer T,et al.Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes, 1990,39:76- 82.
  • 9Lufft V, Kliem V, Hamkens A, et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant, 1998, 12:409-415.
  • 10Rudberg S, Aperia A, Freyschuss U, et al. Enalapril reduces microalbuminuria in young normotensive type 1 (insulindependent) diabetic patients irrespective of its hypotensive effect. Diabetologia, 1990,33:470-476.

共引文献170

同被引文献6

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部